Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PNMT | P11086 | 7/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17785623 | 0.90 | GFER (0.56) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL26812415 | 0.86 | GFER (0.60) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL514685 | 0.86 | PNMT (0.58) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL4230983 | 0.82 | CA1 (0.61) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL30664965 | 0.82 | CA1 (0.61) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL1806454 | 0.82 | GFER (0.59) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL27947100 | 0.82 | SMN1; SMN2 (0.63) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL31591380 | 0.81 | SMN1; SMN2 (0.71) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL8178590 | 0.81 | HTR2C (0.65) | GFERSMN1; SMN2PNMTHDAC3HDAC4 | |
| SCHEMBL1818147 | 0.81 | SMN1; SMN2 (0.71) | GFERSMN1; SMN2PNMTHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| EP-2699562-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20170334907-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-9676768-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-9018214-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-28 | — | — | US | disclosed |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-7803828-B2 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING-PLOUGH CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803828-B2 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING-PLOUGH CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| WO-2008100457-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| WO-2007024944-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | GFER 1885/4885SMN1; SMN2 2213/4885PNMT 2581/4885 |
| US-20170334907-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GFER 2797/4885SMN1; SMN2 1240/4885PNMT 1602/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GFER 2797/4885SMN1; SMN2 1240/4885PNMT 1602/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GFER 2797/4885SMN1; SMN2 1240/4885PNMT 1602/4885 |
| US-20150291586-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GFER 2797/4885SMN1; SMN2 1240/4885PNMT 1602/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GFER 2797/4885SMN1; SMN2 1240/4885PNMT 1602/4885 |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | GFER 3374/4885SMN1; SMN2 1464/4885PNMT 259/4885 |
| US-20140179666-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GFER 2797/4885SMN1; SMN2 1240/4885PNMT 1602/4885 |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | GFER 3374/4885SMN1; SMN2 1464/4885PNMT 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.